Goldman Sachs Group began coverage on shares of Vir Biotechnology (NYSE:VIR) in a research note released on Tuesday, The Fly reports. The firm issued a buy rating and a $37.00 price objective on the stock.
Several other analysts have also recently issued reports on the company. Barclays initiated coverage on Vir Biotechnology in a report on Tuesday. They set an overweight rating and a $25.00 price objective on the stock. JPMorgan Chase & Co. began coverage on Vir Biotechnology in a report on Tuesday. They set an overweight rating and a $25.00 price target on the stock. Finally, Cowen began coverage on Vir Biotechnology in a report on Tuesday. They set an outperform rating on the stock.
VIR stock traded down $0.70 during midday trading on Tuesday, hitting $13.83. The company’s stock had a trading volume of 169,208 shares, compared to its average volume of 214,875. Vir Biotechnology has a 12 month low of $13.39 and a 12 month high of $16.50.
Vir Biotechnology Company Profile
Vir Biotechnology, Inc, a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis.
Recommended Story: Consumer behavior in bull markets
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.